Abstract Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common hereditary disorders. The prevalence of the ADPKD genotype in the Caucasian and Latin populations has been reported. Here, we used linkage analysis to demonstrate the prevalence of the genotype and the correlation between phenotypes and genotypes among 21 Japanese ADPKD families consisting of 96 individuals and including 57 affected members. Six polymorphic markers, each linked to either the polycystic kidney disease 1 (PKD1) or polycystic kidney disease 2 (PKD2) gene, were used for polymerase chain reaction analysis. Seventeen families (81%) showed linkage to PKD1, two families (10%) showed linkage to PKD2, and two families did not show linkage to either PKD1 or PKD2. One of the PKD1-linked families was indicated to have different mutations of PKD1 gene in the same family. PKD2-linked families did not have milder symptoms than PKD1-linked families.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common hereditary disorders. ADPKD is usually adult onset (MacDermot et al. 1998; Watnick et al. 1999) . The prevalence of ADPKD in the Japanese population has been estimated as 1/4033 (Higashihara et al. 1998) , which is much less than among Caucasians. Previous linkage studies showed that approximately 80%-85% of ADPKD families are positively linked to the polycystic kidney disease 1 (PKD1) gene and most of the remainder are linked to the polycystic kidney disease 2 (PKD2) gene (Wright et al. 1993; Bogdanova et al. 1995; Iglesias et al. 1997) . Only a few families not linked either to PKD1 or PKD2 have been reported in Caucasian and Latin populations (Daoust et al. 1995; Almeida et al. 1995 Almeida et al. , 1999 Turco et al. 1996; Ariza et al. 1997) . Correlations between genotypes and phenotypes of ADPKD have also been investigated in those populations (Hateboer et al. 1999) . Many researchers have suggested that the severity of symptoms is greater in patients with PKD1 than in those with PKD2, but the relationship is still not clear. We performed linkage analysis to demonstrate the distribution of the genotypes and the difference of phenotypes among the genotypes in 21 Japanese ADPKD families.
Subjects and methods
Patient recruitment. ADPKD families were recruited nationwide through their family doctors at the request of the ADPKD research group, supported by the Ministry of Health and Welfare of Japan. Family members were evaluated ultrasonographically with symptomatic affected subjects showing at least five more cysts bilaterally in the kidneys. Family doctors took blood samples from individuals after obtaining informed consent. Each family in this study included at least two affected members and a minimum of two unaffected siblings, parents, and/or children.
DNA preparation. Genomic DNA was extracted from peripheral blood lymphocytes by standard methods, using phenol/chloroform extraction and isopropanol precipitation.
Polymerase chain reaction and data analysis. To assess linkage to PKD1, two intragenic (KG8, I42) and four other markers for PKD1 were used. I42 is a polymorphic marker within intron 42 of the PKD1 gene. This marker has sequences of tandem repeats, for example, between nucleotides 50155 and 50436. KG8 is a microsatellite marker in the 3Ј untranslated region of the PKD1 gene (Snarey et al. 1994) . Microsatellite markers 16AC2.5, CW2, SM7 are localized within 350 kb of the PKD1 gene (Harris et al. 1991; Thompson et al. 1992; Viribay et al. 1994) . Microsatellite marker D16S521 is located distal to the PKD1 gene (Coto et al. 1995) . To assess linkage to PKD2, six markers, D4S231, D4S1534, D4S1542, D4S1563, D4S1544, and D4S414 (Mills et al. 1992) , were used. The 5Ј end of one of the paired primers was labeled with X-rhodamine isothiocyanate (XRITC) and used for polymerase chain reaction (PCR). PCR was performed as reported previously with slight modifications. PCR products were separated electrophoretically on a 40-cm length of 8% polyacrylamide gel containing 7 M urea at 18 W for 4h. Allele patterns were analyzed with an FMBIO 100 fluoro-imager (Takara, Kusatsu, Japan).
Results

Heterozygosity of PKD1 and PKD2 markers
Twelve markers used in this study were selected as polymorphic markers. The heterozygosity in the Japanese population was analyzed using genomic DNA from 80 unrelated Japanese individuals. In I42 marker there were five different sizes of alleles and 47% of the heterozygosities was shown (Table 1 ). All were indicated to be useful markers for linkage analysis.
Linkage analysis
Haplotype analyses were carried out in 21 Japanese families using six markers linked to PKD1 and six to PKD2. The families consisted of 96 individuals, 45 males and 51 females, including 57 affected members. Three-point linkage analysis was performed between the distal and proximal markers for PKD1 and PKD2 that were informative and located at the most flanking locus in each family. Maximum lod scores are shown for each respective θ value (Table 2) . We determined the genotype by the positive or negative lod scores to the PKD1 or PKD2 markers. Sixteen families showed linkage to PKD1. Two families, K38 and K84, showed linkage to PKD2, and three families, K68, K71 and K123, did not show linkage to either PKD1 or PKD2. In family K68, which did not show linkage to either PKD1 or PKD2, only two out of three affected sibs had the same haplotype. The nonsense mutation Q4124X in exon 45 was found only in the two members with the same haplotype, but not in the one with the different haplotype (Mizoguchi et al. 2001 ). This family was also screened for PKD2 gene mutations, but no mutation was found. Because of the mutation data, family K68 was included in the group of PKD1-linked families.
Clinical symptoms and genotypes
Comparative clinical symptoms of 57 affected individuals with PKD1, PKD2, and non-PKD1 or PKD2 genotypes are shown in Table 3 . Forty-nine percent of these individuals were on treatment for hypertension, 39% were positive for liver cysts, and 23% were on hemodialysis; 4% had ischemic heart disease, and 5% had cerebral hemorrhage. In the PKD1-linked families, 4 out of 20 patients had hypertension in their second decade, and 67% of the patients had hemodialysis treatment before 60 years of age. 
Discussion
Genotypes in the Japanese population
The family size in our study was relatively small (average 4.5 individuals). Sixteen of the ADPKD families were positively linked to PKD1. Since a PKD1 mutation was found in family K68, this family was included among those with the PKD1 genotype, so there were 17 PKD1-linked families (81%) among the 21 families. This is almost same proportion of genetic heterogeneity reported previously in other populations, such as among Caucasians (81%) (Wright et al. 1993) , Bulgarians (73%) (Bogdanova et al. 1993) , and Argentinians (91%) (Iglesias et al. 1997 ). There has been some doubt about the existence of a third ADPKD gene (Paterson and Pei 1998) . Recently, bilineal disease and trans-heterozygotes were found in a large ADPKD family that had been previously assigned to a third PKD-gene linked family. PKD1 and PKD2 mutations segregated independently in this large family (Pei et al. 2001) . Family K68 showed the possibility of bilineal ADPKD disease because of different mutations of the PKD1 gene, although only one mutation was identified (Mizoguchi et al. 2001) . In family K123, with no linkages to either PKD1 or PKD2, one 11-year-old child was affected, but another, 13 years old, was not affected at the time of the study. This child may acquire cysts with age. In the two families (K71 and K123) not linked to either gene, no mutations in the unique region of PKD1 or in exons of PKD2 have yet been identified. Thus, we could not determine whether a third gene for ADPKD is present in these families.
Clinical symptoms and genotypes
The occurrence of clinical symptoms was lower than reported previously, but patients with hypertension and undergoing hemodialysis treatment showed early onset (Gabow 1993) . Eight of the patients in this study were younger than 20 years old, and none had any clinical symptoms at the time of their diagnosis. More individuals may become symptomatic in the future. Differences in the severity of symptoms between patients with PKD1 and those with PKD2 were not clear in this study because only two families were linked to PKD2. But these two PKD2-linked families did not display milder symptoms than the average among PKD-linked families. 
